Elastic compression stockings one year after DVT diagnosis: Who might discontinue?


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
01 2019
Historique:
received: 15 08 2018
revised: 13 10 2018
accepted: 02 11 2018
pubmed: 24 11 2018
medline: 6 3 2019
entrez: 24 11 2018
Statut: ppublish

Résumé

Elastic compression stockings (ECS) are uncomfortable to wear but may prevent post-thrombotic syndrome (PTS). The ability to predict PTS may help clinical decision making regarding the optimal duration of ECS after deep vein thrombosis (DVT). Predefined endpoint analysis of the Octavia study that randomized patients who compliantly used ECS up to one year after DVT to continue or discontinue ECS treatment. Primary aim was to identify predictors of PTS. Patient characteristics were collected and ultrasonography was performed to assess reflux, residual thrombosis and persistent thrombus load 12 months after DVT. Multivariable analyses were performed to identify factors related to PTS. Thrombus score ≥ 3, BMI ≥ 26, duration of symptoms before DVT diagnosis ≥ 8 days and a Villalta score of 2-4 points were statistically significant predictors of PTS. The predictive value for PTS for the assessed variables was not different between the 2 treatment groups. In the stop ECS group, 3.2% (95%CI 0.08-18) of patients without any predictors for PTS were diagnosed with mild PTS during follow-up, and none with severe PTS, for a sensitivity of 98% (95% CI 89-100), a specificity of 14% (95% CI 10-20), a positive predictive value of 20% (95% CI 19-22), and a negative predictive value of 97% (95% CI 81-100). We identified 4 predictors of PTS occurring in the 2nd year after DVT. Our findings may be used to decide on whether to continue ECS treatment for an additional year, after one year of compliant ECS use, keeping in mind that patients with none of the predictors will have the lowest PTS incidence.

Sections du résumé

BACKGROUND
Elastic compression stockings (ECS) are uncomfortable to wear but may prevent post-thrombotic syndrome (PTS). The ability to predict PTS may help clinical decision making regarding the optimal duration of ECS after deep vein thrombosis (DVT).
AIMS
Predefined endpoint analysis of the Octavia study that randomized patients who compliantly used ECS up to one year after DVT to continue or discontinue ECS treatment. Primary aim was to identify predictors of PTS.
METHODS
Patient characteristics were collected and ultrasonography was performed to assess reflux, residual thrombosis and persistent thrombus load 12 months after DVT. Multivariable analyses were performed to identify factors related to PTS.
RESULTS
Thrombus score ≥ 3, BMI ≥ 26, duration of symptoms before DVT diagnosis ≥ 8 days and a Villalta score of 2-4 points were statistically significant predictors of PTS. The predictive value for PTS for the assessed variables was not different between the 2 treatment groups. In the stop ECS group, 3.2% (95%CI 0.08-18) of patients without any predictors for PTS were diagnosed with mild PTS during follow-up, and none with severe PTS, for a sensitivity of 98% (95% CI 89-100), a specificity of 14% (95% CI 10-20), a positive predictive value of 20% (95% CI 19-22), and a negative predictive value of 97% (95% CI 81-100).
CONCLUSION
We identified 4 predictors of PTS occurring in the 2nd year after DVT. Our findings may be used to decide on whether to continue ECS treatment for an additional year, after one year of compliant ECS use, keeping in mind that patients with none of the predictors will have the lowest PTS incidence.

Identifiants

pubmed: 30468951
pii: S0049-3848(18)30596-6
doi: 10.1016/j.thromres.2018.11.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-41

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

G C Mol (GC)

Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands; Department of Internal Medicine, Meander Medical Center, Amersfoort, the Netherlands.

C E A Dronkers (CEA)

Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: C.E.A.Dronkers@lumc.nl.

M A van de Ree (MA)

Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands.

S L van der Pas (SL)

Medical Statistics Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands; Mathematical Institute, Leiden University, Leiden, the Netherlands.

M J A M Tegelberg-Stassen (MJAM)

Department of Dermatology, Diakonessenhuis Hospital, Utrecht, the Netherlands.

F B M Sanders (FBM)

Department of Radiology, Diakonessenhuis Hospital, Utrecht, the Netherlands.

S Koppen (S)

Department of Dermatology, St. Antonius Hospital, Nieuwegein, the Netherlands.

O de Weerdt (O)

Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, the Netherlands.

T Koster (T)

Department of Internal Medicine, Groene Hart Hospital, Gouda, the Netherlands.

M M C Hovens (MMC)

Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands.

H A H Kaasjager (HAH)

Department of Internal Medicine, University Medical Center, Utrecht, the Netherlands.

R E Brouwer (RE)

Department of Internal Medicine, Reinier de Graaf Group, Delft, the Netherlands.

E Kragten (E)

Department of Internal Medicine, Reinier de Graaf Group, Delft, the Netherlands.

C G Schaar (CG)

Department of Internal Medicine, Gelre Hospitals, Apeldoorn, the Netherlands.

W Spiering (W)

Department of Internal Medicine, University Medical Center, Utrecht, the Netherlands.

W P Arnold (WP)

Department of Dermatology, Gelderse Vallei Hospital, Ede, the Netherlands.

M V Huisman (MV)

Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.

F A Klok (FA)

Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH